Literature DB >> 19630714

Use of caffeine and nicotine in people with schizophrenia.

Jill M Williams1, Kunal K Gandhi.   

Abstract

There are numerous reports of increased use of both caffeine and nicotine in schizophrenia. Clinical effects of these substances are important and may complicate the interpretation of schizophrenia symptoms and antipsychotic medication side effects. Use of caffeine and nicotine is often linked, with smokers using more caffeine due to interacting metabolic effects. Studies of neurobiology reveal evidence of specific brain changes in schizophrenia that are impacted by nicotine and caffeine and suggest self-medication effects. Interestingly both substances are linked to altered inhibitory mechanisms in brain functioning. Few studies have examined both simultaneously which is critical given their metabolic and symptomatic interactions. This paper reviews use of caffeine and nicotine in people with schizophrenia and gives recommendations for their further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19630714     DOI: 10.2174/1874473710801020155

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  8 in total

1.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

Review 2.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

3.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

4.  Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.

Authors:  Amy B Adolfo; Christopher G AhnAllen; Jennifer W Tidey
Journal:  Schizophr Res       Date:  2008-11-08       Impact factor: 4.939

Review 5.  Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology.

Authors:  Miroslav Pohanka
Journal:  Int J Mol Sci       Date:  2012-02-17       Impact factor: 6.208

Review 6.  Effect of pharmacological manipulations on Arc function.

Authors:  Dina W Yakout; Nitheyaa Shree; Angela M Mabb
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-24

7.  Using Mendelian randomization analysis to better understand the relationship between mental health and substance use: a systematic review.

Authors:  Jorien L Treur; Marcus R Munafò; Emma Logtenberg; Reinout W Wiers; Karin J H Verweij
Journal:  Psychol Med       Date:  2021-05-25       Impact factor: 7.723

8.  Retinal Microvasculature in Schizophrenia.

Authors:  Steven M Silverstein; Adriann Lai; Kyle M Green; Christen Crosta; Samantha I Fradkin; Rajeev S Ramchandran
Journal:  Eye Brain       Date:  2021-07-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.